Literature DB >> 32952539

Retracted: Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms.

.   

Abstract

[This retracts the article DOI: 10.1155/2008/649808.].
Copyright © 2020 .

Entities:  

Year:  2020        PMID: 32952539      PMCID: PMC7481910          DOI: 10.1155/2020/9469261

Source DB:  PubMed          Journal:  PPAR Res            Impact factor:   4.964


PPAR Research has retracted the article titled “Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms” due to figure duplication. As raised on PubPeer [2], Figure 3C shows several issues: For PPARγ, lanes 1, 2, and 3 appear similar For PPARγ, lanes 6, 7, 9, and 11 all appear similar For PPARγ, lanes 8 and 10 appear similar For MMP-2, lanes 1 and 7 appear similar; likewise lanes 3 and 8 For VEGF, lanes 8 and 11 appear similar For β-actin, lanes 1, 2 appear similar to lanes 7, 8 For β-actin, lanes 5, 9, and 11 appear similar At revision, the authors replaced the Western Blots in Figures 2B and 2D in the submitted article with new Western Blots in Figure 3C to consolidate the results into one blot and add results for VEGF with GW9662, which had been missing in the submitted version. The authors say Figure 3C does match the text description in the article, is not their experimental result, and they do not know how it was included in the article.
  1 in total

1.  Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARgamma Dependent and Independent Mechanisms.

Authors:  Qing He; Ruiping Pang; Xin Song; Jie Chen; Huixin Chen; Baili Chen; Pinjin Hu; Minhu Chen
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.